ASCO 2026 | Anti-tumor activity of liposomal topotecan in patients with advanced Merkel cell carcinoma
Vincent Ma, MD, University of Wisconsin, Madison, WI, discusses the anti-tumor activity of FF-10850, a liposomal formulation of topotecan, in patients with advanced Merkel cell carcinoma, highlighting its potential as a novel agent in a disease with limited treatment options following progression on PD-1-based therapy. Dr Ma notes that a Phase I trial (NCT04047251) demonstrated promising responses, with two out of nice patients achieving an objective response and six out of nine achieving stable disease control, as well as improved progression-free survival (PFS) and a slight improvement in overall survival (OS). This interview took place during the 2026 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
